Journal
IMMUNOTHERAPY
Volume 8, Issue 6, Pages 705-719Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0014
Keywords
cancer; checkpoint inhibitors; DNMT inhibitor; epigenetics; HDAC inhibitor; immunotherapy
Categories
Funding
- NIH [R01 1R01CA152989-01A1]
Ask authors/readers for more resources
Immune surveillance should be directed to suppress tumor development and progression, involving a balance of coinhibitory and costimulatory signals that amplify immune response without overwhelming the host. Immunotherapy confers durable clinical benefit in 'immunogenic tumors', whereas in other tumors the responses are modest. Thus, immune checkpoint inhibitors may need to be combined with strategies to boost immune response or increase the tumor immune profile. Epigenetic aberrations contribute significantly to carcinogenesis. Recent findings suggest that epigenetic drugs prime the immune response by increasing expression of tumor-associated antigens and immune-related genes, as well as modulating chemokines and cytokines involved in immune system activation. This review describes our current understanding regarding epigenetic and immunotherapy combination, focusing on immune response priming to checkpoint blockade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available